Tempest Therapeutics (TPST) FCF Margin (2015 - 2018)
Tempest Therapeutics (TPST) posted FCF Margin of 8610.91% for Q3 2018, down 48.18% sequentially from 5811.11% in Q2 2018, and up 980873.0% YoY from N/an in Q3 2017.
Tempest Therapeutics (TPST) FCF Margin (2015 - 2018) Analysis & Trends
Tempest Therapeutics has reported FCF Margin for 4 years, with the latest figure at 8610.91% in Q3 2018.
- Quarterly FCF Margin rose 980873.0% year-over-year to 8610.91% in Q3 2018, while the trailing twelve-month figure through Sep 2018 was 988.44% (up 1771714.0% YoY) and the FY2017 annual result came in at 6896.27%, up 295365.0% from the prior year.
- FCF Margin retreated to 8610.91% in Q3 2018 per TPST's latest filing, from 5811.11% in the prior quarter.
- Over five years, FCF Margin peaked at 19062.64% in Q4 2017 and troughed at 98553.33% in Q1 2015.
- A 4-year average of 17968.38% and a median of 10808.22% in 2016 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2016 and 2017: FCF Margin jumped 8774511 bps in 2016, then tumbled 1341400 bps in 2017.
- Over 4 years, FCF Margin stood at 9060.51% in 2015, then sank by 51 bps to 13644.63% in 2016, then soared by 240 bps to 19062.64% in 2017, then tumbled by 145 bps to 8610.91% in 2018.
- According to Business Quant data, FCF Margin over the past three periods registered 8610.91%, 5811.11%, and 7459.7% for Q3 2018, Q2 2018, and Q1 2018 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 70.82% |
| 10 | Tempest Therapeutics | 4.32 Mn | 3.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | -8,610.91% |
| Jun 30, 2018 | -5,811.11% |
| Mar 31, 2018 | -7,459.70% |
| Dec 31, 2017 | 19,062.64% |
| Sep 30, 2017 | -18,419.64% |
| Jun 30, 2017 | -14,423.81% |
| Mar 31, 2017 | -24,222.22% |
| Dec 31, 2016 | -13,644.63% |
| Sep 30, 2016 | -7,925.38% |
| Jun 30, 2016 | -8,686.24% |
| Mar 31, 2016 | -10,808.22% |
| Dec 31, 2015 | -9,060.51% |
| Sep 30, 2015 | -18,262.67% |
| Jun 30, 2015 | -42,700.00% |
| Mar 31, 2015 | -98,553.33% |